Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28071885 | 0.97 | CETP (0.30) | CETP | |
| SCHEMBL13165170 | 0.85 | — | — | |
| SCHEMBL9941147 | 0.80 | — | — | |
| SCHEMBL3190278 | 0.78 | — | — | |
| SCHEMBL2852867 | 0.76 | CETP (0.39) | CETP | |
| SCHEMBL2262667 | 0.76 | CETP (0.39) | CETP | |
| SCHEMBL199 | 0.76 | CETP (0.39) | CETP | |
| SCHEMBL5272698 | 0.76 | — | — | |
| SCHEMBL5698414 | 0.73 | — | — | |
| SCHEMBL13325163 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108727903-B | Zinc oxide-based nanoparticle ink and quantum dot light-emitting diode | 苏州星烁纳米科技有限公司 | 2021-10-19 | — | — | CN | claimed |
| EP-2459182-B1 | INJECTABLE FORMULATION FOR TREATMENT AND PROTECTION OF PATIENTS HAVING AN INFLAMMATORY REACTION OR AN ISCHEMIA-REPERFUSION EVENT | UNIV OF ZÜRICH (CH) | 2017-09-06 | — | — | EP | claimed |
| US-9296678-B2 | Injectable formulation for treatment and protection of patients having an Inflammatory Reaction or an Ischemia-reperfusion event | UNIVERSITY OF ZURICH (CH) | 2016-03-29 | — | — | US | claimed |
| US-20140100278-A1 | Injectable Formulation for Treatment and Protection of Patients Having an Inflammatory Reaction or an Ischemia-Reperfusion Event | ETH ZURICH (CH) | 2014-04-10 | — | — | US | claimed |
| US-20120219596-A1 | INJECTABLE FORMULATION FOR TREATMENT AND PROTECTION OF PATIENTS HAVING AN INFLAMMATORY REACTION OR AN ISCHEMIA-REPERFUSION EVENT | Stark, Wendelin (CH) | 2012-08-30 | — | — | US | claimed |
| WO-2010002175-A2 | RESIN COMPOSITION FOR CLADDING OF OPTICAL FIBER | SSCP CO., LTD. (KR) | 2010-01-07 | — | — | WO | claimed |
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| US-6878821-B2 | Contacting with oxidizing agent and fluorinated alcohol | WARNER-LAMBERT LLC (US) | 2005-04-12 | — | — | US | claimed |
| US-20010048977-A1 | Manufacturing method for multilayer fluorescent information carriers | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-12-06 | — | — | US | claimed |
| WO-2001053065-A1 | MANUFACTURING METHOD FOR MULTILAYER FLUORESCENT INFORMATION CARRIERS | TRID STORE IP, LLC (US) | 2001-07-26 | — | — | WO | claimed |
| US-4024165-A | OLEFIN, HYDROGEN PEROXIDE, FLUORINATED ALCOHOL | SHELL OIL COMPANY (US) | 1977-05-17 | — | — | US | claimed |
| JP-6346096-A | — | — | None | — | — | JP | disclosed |
| JP-6346095-A | — | — | None | — | — | JP | disclosed |
| US-20250309352-A1 | ELECTROLYTIC SOLUTION FOR LITHIUM-ION SECONDARY BATTERY, AND LITHIUM-ION SECONDARY BATTERY | MURATA MANUFACTURING CO., LTD. (JP) | 2025-10-02 | — | — | US | disclosed |
| US-20240410055-A1 | METHOD AND FORMULATION FOR PREPARING OPTICAL METAL OXIDE LAYERS | MERCK PATENT GMBH (DE) | 2024-12-12 | — | — | US | disclosed |
| JP-H06346096-A | FLUORINATED ALCOHOL CLEANSER | AGENCY OF IND SCIENCE & TECHNOL | 1994-12-20 | — | — | JP | disclosed |
| JP-H06346095-A | FLUORINE BASED CLEANSING SOLVENT COMPOSITION | AGENCY OF IND SCIENCE & TECHNOL | 1994-12-20 | — | — | JP | disclosed |
| EP-0096130-A1 | Process for the epoxidation of olefins | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1983-12-21 | — | — | EP | disclosed |
| US-4418203-A | PHENYL ALLYL ETHERS, CATALYSIS, FLUORINATED ALCOHOL SOLVENTS | SHELL OIL COMPANY (US) | 1983-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120219596-A1 | INJECTABLE FORMULATION FOR TREATMENT AND PROTECTION OF PATIENTS HAVING AN INFLAMMATORY REACTION OR AN ISCHEMIA-REPERFUSION EVENT | HIF1A, HIF1AN, PGF | CETP 1438/4885 |
| US-20140100278-A1 | Injectable Formulation for Treatment and Protection of Patients Having an Inflammatory Reaction or an Ischemia-Reperfusion Event | HIF1AN, HIF1A, PGF | CETP 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.